Your browser doesn't support javascript.
loading
Updated Clinical Outcomes of Hematopoietic Stem Cell Transplantation Using Myeloablative Total Body Irradiation with Ovarian Shielding to Preserve Fertility.
Ashizawa, Masahiro; Akahoshi, Yu; Nakano, Hirofumi; Kawamura, Shunto; Takeshita, Junko; Yoshino, Nozomu; Misaki, Yukiko; Yoshimura, Kazuki; Gomyo, Ayumi; Tamaki, Masaharu; Kusuda, Machiko; Kameda, Kazuaki; Wada, Hidenori; Kawamura, Koji; Sato, Miki; Terasako-Saito, Kiriko; Tanihara, Aki; Kimura, Shun-Ichi; Nakasone, Hideki; Kako, Shinichi; Akahane, Keiko; Wakatsuki, Masaru; Shirai, Katsuyuki; Kanda, Yoshinobu.
Afiliación
  • Ashizawa M; Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
  • Akahoshi Y; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Nakano H; Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
  • Kawamura S; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Takeshita J; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Yoshino N; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Misaki Y; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Yoshimura K; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Gomyo A; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Tamaki M; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Kusuda M; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Kameda K; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Wada H; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Kawamura K; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Sato M; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Terasako-Saito K; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Tanihara A; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Kimura SI; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Nakasone H; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Kako S; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Akahane K; Division of Radiology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Wakatsuki M; Department of Radiology, Jichi Medical University, Tochigi, Japan.
  • Shirai K; Division of Radiology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Kanda Y; Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan. Electronic address: ycanda-tky@umin.ac.jp.
Biol Blood Marrow Transplant ; 25(12): 2461-2467, 2019 12.
Article en En | MEDLINE | ID: mdl-31394267
ABSTRACT
Myeloablative conditioning regimens are associated with severe gonadal toxicity. To preserve ovarian function, we have been investigating ovarian shielding during total body irradiation (TBI) with a myeloablative dose. In this report, we update the clinical outcomes. Female patients with standard-risk hematologic diseases, aged 40 years or younger, who desired to have children, were included (n = 19). The conditioning regimen consisted of TBI at 12 Gy with ovarian shielding and cyclophosphamide (120 mg/kg) or cytarabine (24 g/m2). Ovarian shielding reduced the actual irradiation dose applied to the ovaries from 12 Gy to 2 to 3 Gy. The median age at hematopoietic stem cell transplantation (HSCT) was 24 years (range, 19 to 33 years). With a median follow-up period of 1449 days (range, 64 to 3694) after HSCT, 5-year overall survival and 1- and 5-year relapse rates were 67%, 17%, and 31%, respectively. Only 2 of 14 patients with acute myeloid or lymphoid leukemia in remission have relapsed thus far. The 6-month and 1-year cumulative rates of menstrual recovery were 42% and 78%, respectively. In all patients with menstrual recovery, menstruation recovered within 1 year. The serum anti-Müllerian hormone (AMH) level tended to gradually increase after menstrual recovery. Three patients with extensive chronic graft-versus-host disease experienced delayed recovery of menstruation and serum AMH. Five pregnancies in 3 patients resulted in normal delivery in 1, selective cesarean operation in 1, current pregnancy in 1, and natural abortion in 2. These results suggest that a myeloablative TBI regimen with ovarian shielding could preserve fertility after HSCT without an apparent increase in relapse in standard-risk patients. Because serum AMH recovered gradually over time, the AMH level during the early phase after HSCT may have little value as a marker of ovarian reserve.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ovario / Irradiación Corporal Total / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Acondicionamiento Pretrasplante / Preservación de la Fertilidad Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ovario / Irradiación Corporal Total / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Acondicionamiento Pretrasplante / Preservación de la Fertilidad Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article País de afiliación: Japón